This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Thienopyridines

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the two related thienopyridine derivatives, ticlopidine and clopidogrel, are specific inhibitors of the P2Y12 ADP receptor
  • both drugs are inactive and metabolised in the liver
  • ticlodipine has uncommon (0.5-3%) but very serious haematological toxicity including neutropaenia, thrombocytopaenia, thrombotic thrombocytopaenia purpura and (very rarely) aplastic anaemia (1); gastrointestinal side effects and rash are common
  • clopidogrel has a significantly better safety profile than ticlodipine
    • clopidogrel has been associated with gastrointestinal upset and bleeding, but at lower rates than those observed with aspirin
    • there have been a number of reports associating clopidogrel with thrombocytopaenic purpura, neutropaenia and aplastic anaemia; however, this risk has to be put into perspective with over 17,000 patients having been treated, at the time of writing, with clopidogrel in randomised controlled trials with no increased incidence of thrombocytopaenia or neutropaenia noted

Reference:

  1. Patrano C et al.Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.